Jesus Muñoz: None declared, Luis Del Río: None declared, Marta Arévalo: None declared, Menna Rushhol: None declared, Noemi Navarro: None declared, Victor Parejo: None declared, Jordi Gratacos-Masmullà Grant/research support: from: a grant from Pfizer to study implementation of multidisciplinary units to manage PSA in SPAIN, Consultant of: Pfizer, MSD, ABBVIE, Janssen, Amgen, BMS, Novartis, Lilly, Speakers bureau: Pfizer, MSD, ABBVIE, Janssen, Amgen, BMS, Novartis, Lilly

**DOI:** 10.1136/annrheumdis-2020-eular.2644

**SAT0469**

**PROSPECTIVE STUDY ASSESSING BONE MINERAL DENSITY AND RISK FACTORS FOR OSTEOPOROSIS IN PATIENTS WITH ANDROGEN DEPRIVATION THERAPY. PRELIMINARY CROSS-SECTIONAL RESULTS**

L. Gilfe1, F. Elias2, P. Servián3, R. Freixa4, O. Buisan Rueda5, Hospital Universitari Germans Trias i Pujol, Rheumatology, Badalona, Spain; 2Hospital Universitari Germans Trias i Pujol, Urology, Badalona, Spain

**Background:** Few studies have analysed the incidence and risk factors for osteoporosis (OP) development in patients with prostate cancer (PC) and androgen deprivation therapy (ADT).

**Objectives:** To assess risk factors for OP, bone turnover markers (BTM) and bone mineral density (BMD) in a cohort of patients with ADT, as well as the changes of OP, BTM and previous treatments received during ADT.

**Methods:** Ongoing prospective study including patients with ADT for PC. Risk factors for OP, BTM (total ALP, bone ALP, CTx), spinal X-Ray and BMD (Lunar, DPX) were assessed yearly since inclusion in the study (April 2018). Patients with known OP or previous antosteoporotic treatment were excluded. The study was approved by the ethics committee, and all patients gave their signed consent. Herein we present the preliminary cross-sectional study at inclusion.

**Results:** Of the 83 patients attended at the Rheumatology Department during the study period, 75 were included with a mean age 75±5years and median ADT duration of 1 year. 18 were receiving concomitant radiotherapy and 7 docetaxel. When assessing risk factors for OP: 28% had previous fragility fractures and 24% had current alcohol intake. After X-Ray assessment, 14% had morphometric vertebral fractures. Mean 25OHD at inclusion was 19.3ng/ml (73% had 25OHD <30ng/ml) and mean testosterone was 82±162ng/dL (75% had levels <50ng/dl). All patients had increased values of CTx and 9% had increased bone ALP levels. BMD showed up to 28% with densitometric OP and osteopenia in 56%. Patients with OP were older (83±7 vs 74±8 years, p<0.02), had lower testosterone levels (16 vs 89ng/dl, p<0.004), as expected lower BMD (at spinal, proximal femur and even distal radius) and had more previous fragility fracture (75 vs 19%, p=0.022). But it should be noted that 16% had high bone mass (HBM) mostly affecting spine BMD (in 6 patients combined with femoral osteopenia). All patients with HBM had high bone metastatic disease, and no differences were observed between patients with/without HBM when comparing BTM or calcium-phosphate metabolism.

**Conclusion:** Low bone mass (including osteoporosis and osteopenia) is frequent in patients with ADT as well as previous fragility fractures. Up to 16% had high bone mass, being mostly in patients with high volume metastatic disease. Thus, all patients with ADT should undergo a bone health assessment and start antosteoporotic treatment if required.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.5204

**SAT0470**

**FRAX AND DXA-BASED APPROACHES IN DIAGNOSTICS OF OSTEOPOROSIS RISK IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS**

N. Grygorieva1, V. Povoroznyuk1, N. Dzerovych1, M. Bystrytska1, 1State Institution «D.F. Chebotarev Institute of Gerontology NAMS of Ukraine», Department of Clinical Physiology and Pathology of Locomotor Apparatus, Kyiv, Ukraine

**Background:** Nowadays, the bone mineral density (BMD) measured by DXA and FRAX® are the most important methods for fracture risk assessment. Rheumatoid arthritis is a crucial disease for bone loss and osteoporosis development which is included into FRAX algorithm. Ukrainian version of FRAX [2] is а new model of the FRAX algorithm. The 10-year probabilities of hip fracture and major osteoporotic fractures were significantly higher in patients with RA (Me [25-75Q]: 9.7 [6.8-15.0] and 3.1 [1.5-6.2]) compared to 6.0 [3.8-8.5] and 1.2 [0.6-2.4] % in females from the control group (p<0.001), 45.3 % of women with RA required antosteoporotic treatment according to Ukrainian FRAX threshold ratio without measure of BMD compared to 12.1% of subjects from control group. Only 3.4% of patients with RA had FRAX indexes which were less than low threshold (requirement of additional DXA measurement) compared to 31.3 % of females from control group (p<0.001). BMD of femoral neck and distal radius were relatively lower in subjects with RA and consisted 0.65±0.13 and 0.69±0.12g/cm in 1 and 2 groups, accordingly (p<0.001) and 0.56±0.10 and 0.58±0.09g/cm (p=0.02) without any significant differences at lumbar spine and total body BMDs. 16.6 % of subjects from the control group and 31.6 % of females with RA had osteoporosis according to DXA parameters (T-score ≤-2.5 SD).

**Conclusion:** FRAX should be used more widely in clinical practice for detection of risk of osteoporotic fractures in subjects with RA.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.6028

**SAT0471**

**EFFECTS OF ONE YEAR TOFACITINIB THERAPY ON BONE DENSITY AND BIOMARKERS OF BONE TURNOVER IN RHEUMATOID ARTHRITIS**


**Background:** Oral JAK inhibitors, tofacitinib appeared as a new therapeutic option beside biological therapies, which has already proven its safety and effectiveness in RA, but we lack of knowledge how it affects density of bone structures and bone turnover markers.

**Objectives:** The aim of this study was to assess the effects of one-year tofacitinib therapy on bone metabolism in patients with RA.

**Methods:** Altogether 30 RA patients with active disease were recruited and treated with tofacitinib in this 12-months follow-up study. Mean age of patients were 52.8±10.0 years, duration of rheumatoid arthritis were 7.7±5.0 years. Half of the patients haven’t received biological treatment prior tofacitinib therapy, other half of the patients switched to tofacitinib therapy after completing washout. 15 patients received 2x5mg and 15 patients received 2x10mg tofacitinib daily for 12 months. On both arms 2-2 patients have discontinued treatment and excluded from the study. Measurements were performed at baseline, month 6 and 12. Levels of CRP and IgM rheumatoid factor (RF) antibodies were measured by quantitative nephelometry and levels of anti-CCP, sclerostin, osteocalcin (OC), P1NP were assessed by ELISA. Bone density was assessed by DXA (dual-energy X-ray absorptiometry, Lunar) and pQCT imaging techniques. Levels of DKK1, OPG, RANKL were measured by multiplex microbead immunoassay (Biologen Legend ENDplex). In addition, disease activity (DAS28), age and disease duration were also measured. Correlations were determined by Spearman’s analysis. Univariate and multiple regression analysis using the stepwise method was applied to investigate independent associations between DXA measurements (dependent variables) and laboratory parameters (independent variables).

**Results:** Tofacitinib significantly reduced DAS28 (p<0.001) and HAQ values (p=0.001), also level of CRP (p<0.001) and We (p=0.014). With respect to bone biomarkers we have experienced significant increase in levels of CRP and OPG at month 12. We have found significant increase in levels of P1NP (p=0.027, p=0.005), OPG (p=0.005, p=0.002) and vitamin-D (p=0.001, p=0.004) at month 6 and 12, also in OC at month 6 (p=0.027) in Group A (2x5mg).

In Group B (2x10mg) we’ve experienced a significant decrease in levels of phosphate and CTX at month 6 and 12 (p=0.012, p=0.021, and p=0.005, p=0.007).